

DIABETES CARE[®]

THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION

ORIGINAL ARTICLES

- Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients**
M.-S. WU, P. JOHNSTON, W.H.-H. SHEU, C.B. HOLLENBECK, C.-Y. JENG, I.D. GOLDFINE, Y.-D.I. CHEN, G.M. REAVEN 1
- Impact of Physical Fitness and Glycemic Control on In Vivo Insulin Action in Adolescents With IDDM**
S. ARSLANIAN, P.A. NIXON, D. BECKER, A.L. DRASH 9
- Relationship Between Hyperglycemia and Cognitive Function in Older NIDDM Patients**
G.M. REAVEN, L.W. THOMPSON, D. NAHUM, E. HASKINS 16
- Intracerebral Crises During Treatment of Diabetic Ketoacidosis**
A.L. ROSENBLOOM 22 ✓
- Effect of Pregnancy on Progression of Diabetic Retinopathy**
B.E.K. KLEIN, S.E. MOSS, R. KLEIN 34
- Five-Year Follow-Up Study on Plasma Insulin Levels in Newly Diagnosed NIDDM Patients and Nondiabetic Subjects**
L.K. NISKANEN, M.I. UUSITUPA, H. SARLUND, O. SIITONEN, K. PYÖRÄLÄ 41

REVIEW ARTICLE

- Scope and Heterogeneous Nature of MODY** S.S. FAJANS 49 ✓

SHORT REPORTS

- Survey of Diabetes Professionals Regarding Developmental Changes in Diabetes Self-Care**
T. WYSOCKI, P. MEINHOLD, D.J. COX, W.L. CLARKE 65
- Corrected Q-T Interval Prolongation as Diagnostic Tool for Assessment of Cardiac Autonomic Neuropathy in Diabetes Mellitus**
J.M. GONIN, M.M. KADROFSKE, S. SCHMALTZ, E.J. BASTYR, III, A.I. VINIK 68
- Preservatives in Insulin Preparations Impair Leukocyte Function: In Vitro Study**
I. VAN FAASSEN, A.M.J.J. VERWEIJ-VAN VUGHT, M.Z. LOMECKY-JANOUSEK, P.P.A. RAZENBERG, E.A. VAN DER VEEN 71
- Variation in Absorption of NPH Insulin Due to Intramuscular Injection**
A. VAAG, A. HANDBERG, M. LAURITZEN, J.E. HENRIKSEN, K.D. PEDERSEN, H. BECK-NIELSEN 74

EDITORIAL

- 77

LETTERS AND COMMENTS

- 78

ORGANIZATION SECTION

INFORMATION FOR AUTHORS



In non-insulin-dependent diabetes ...

BREAKFAST-TO-BREAKFAST CONTROL...*One dose a day.*

Upjohn

© 1988 The Upjohn Company



24-hour glycemic control can begin at the breakfast table.

When diet and exercise aren't enough, once-a-day MICRONASE provides 24-hour control of both postprandial and fasting blood glucose levels. The usual starting dosage, 2.5 mg to 5 mg once a day, should be taken with breakfast or the first main meal of the day. Some patients, particularly those receiving more than 10 mg daily, may have a more satisfactory response with twice-a-day dosage.

All sulfonylureas, including MICRONASE, can cause severe hypoglycemia. Proper patient selection, dosage, and instructions are important.

Micronase[®]
Tablets (glyburide) Usual starting dosage
2.5 mg-5 mg once a day

Please see adjacent page for brief summary of prescribing information.

Micronase®

Tablets (glyburide) Usual starting dosage
2.5 mg-5 mg once a day

CONTRAINDICATIONS: MICRONASE Tablets are contraindicated in patients with: 1. Known hypersensitivity or allergy to the drug. 2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin. 3. Type I diabetes mellitus, as sole therapy.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with noninsulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes, 19 [Suppl 2]: 747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: General—Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection and dosage and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: In diabetic patients exposed to stress such as fever, trauma, infection or surgery, a loss of control may occur. It may then be necessary to discontinue MICRONASE and administer insulin. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure. **Information for Patients:** Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Laboratory Tests: Response to MICRONASE Tablets should be monitored by frequent urine glucose tests and periodic blood glucose tests. Measurement of glycosylated hemoglobin levels may be helpful in some patients.

Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Studies in rats at doses up to 300 mg/kg/day for 18 months showed no carcinogenic effects. Glyburide is nonmutagenic when studied in the Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay.

Pregnancy: Teratogenic effects: Pregnancy Category B. Reproduction studies in rats and rabbits have revealed no evidence of impaired fertility or harm to the fetus due to glyburide. There are no adequate and well controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Insulin should be used during pregnancy to maintain blood glucose as close to normal as possible. **Nonteratogenic Effects:** Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. MICRONASE should be discontinued at least two weeks before the expected delivery date.

Nursing Mothers: Some sulfonylurea drugs are known to be excreted in human milk. Insulin therapy should be considered.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: Hypoglycemia: See Precautions and Overdosage sections. **Gastrointestinal Reactions:** Cholestatic jaundice and hepatitis may occur rarely; MICRONASE Tablets should be discontinued if this occurs. Gastrointestinal disturbances (nausea, epigastric fullness, and heartburn) occurred in 1.8% of patients during clinical trials. They were the most commonly reported adverse reactions. They tend to be dose related and may disappear when dosage is reduced. Liver function abnormalities have been reported.

Dermatologic Reactions: Allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5% of patients during trials. These may be transient and may disappear despite continued use of MICRONASE; if skin reactions persist, the drug should be discontinued. **Porphyria cutanea tarda** and photosensitivity reactions have been reported with sulfonylureas.

Hematologic Reactions: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas. **Metabolic Reactions:** Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas; however, hepatic porphyria has not been reported with MICRONASE and disulfiram-like reactions have been reported very rarely. Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. (SIADH) secretion has been reported with certain other sulfonylureas, and it has been suggested that these sulfonylureas may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.

OVERDOSAGE: Overdosage of sulfonylureas, including MICRONASE Tablets, can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate which will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery.

Maximum Dose: Daily doses of more than 20 mg are not recommended.

Dosage Interval: Once-a-day therapy is usually satisfactory. Some patients, particularly those receiving more than 10 mg daily, may have a more satisfactory response with twice-a-day dosage.

Specific Patient Populations: MICRONASE is not recommended for use in pregnancy or for use in children. In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions. (See Precautions Section).

For additional product information see your Upjohn representative.

Upjohn

THE UPJOHN COMPANY, Kalamazoo, MI 49001

B-5-S

May 1988

J-8274

JANUARY AUTHOR INDEX

(Volume 13, Number 1)

Arslanian, S., 9	Moss, S.E., 34
Bastyr, E.J., III, 68	Murdoch, S., 79
Beck-Nielsen, H., 74	Nahum, D., 16
Becker, D., 9	Niskanen, L.K., 41
Bilo, H.J.G., 80	Nixon, P.A., 9
Bone, A.J., 81	Pedersen, K.D., 74
Chen, Y.-D.I., 1	Phatek, R.B., 81
Clarke, W.L., 65	Popp-Snijders, C., 80
Cox, D.J., 65	Pyörälä, K., 41
Dean, H.J., 78	Raheja, B.S., 81
Drash, A.L., 9	Razenberg, P.P.A., 71
Fajans, S.S., 49	Reaven, G.M., 1, 16
Goldfine, I.D., 1	Roe-Finlay, S., 78
Gonin, J.M., 68	Rosenbloom, A.L., 22
Handberg, A., 74	Sarlund, H., 41
Haskins, E., 16	Schmaltz, S., 68
Heine, R.J., 80	Sheu, W.H.-H., 1
Henriksen, J.E., 74	Sitonen, O., 41
Hollenbeck, C.B., 1	Sparkes, P., 79
Jeng, C.-Y., 1	Thompson, L.W., 16
Jennings, A.M., 79	Uusitupa, M.I., 41
Johnston, P., 1	Vaag, A., 74
Kadrofske, M.M., 68	Van der Veen, E.A., 71
Klein, B.E.K., 34	Van Faassen, I., 71
Klein, R., 34	Verweij-van Vught, A.M.J.J., 71
Lauritzen, M., 74	Vinik, A.I., 68
Lomecky-Janousek, M.Z., 71	Ward, J.D., 79
Mackinnon, M., 79	Webster, K.A., 81
Meinhold, P., 65	Wilkin, T.J., 81
	Wilson, R.M., 79
	Wu, M.-S., 1
	Wysocki, T., 65

EDITOR IN CHIEF

David C. Robbins, MD

ASSOCIATE EDITORS

Jorge Calles-Escandon, MD
Kenneth C. Copeland, MD
John T. Devlin, MD
Richard P. Tonino, MD

EDITORIAL ASSISTANT

India Tresselt

REVIEW EDITOR

Ralph A. DeFronzo, MD

ASSOCIATE EDITORS

K. George M.M. Alberti, MD
Eleuterio Ferrannini, MD
Ronald Kahn, MD
Gerald Reaven, MD
Robert Sherwin, MD
Jay Skyler, MD

EDITORIAL ASSISTANT

Rhonda A. Wolfe

EDITORIAL BOARD

Naji N. Abumrad, MD
Barbara J. Anderson, PhD
Linda A. Anderson, PhD
Ben Brouhard, MD
John Cunningham, PhD
Janice A. Drass, RN, BSN, CDE
Stephen Duck, MD
Jeffrey S. Flier, MD
Carelyn P. Fylling, RN, MS
Robert Gelfand, MD
Richard F. Hamman, MD, PhD
Barbara Howard, PhD
Eli Ipp, MD
Jonathan Jaspán, MD
Barbara Klein, MD, MPH
Ronald LaPorte, PhD
Patrick Lustman, PhD
David G. Marrero, PhD
Robert S. Mecklenburg, MD
Piero Micossi, MD
David M. Nathan, MD
Alyne T. Ricker, MD
Neil Ruderman, MD
Christopher P. Saudek, MD
Robert S. Schwartz, MD
Rena Wing, PhD
Robert R. Wolfe, PhD

PUBLISHER

Caroline Stevens

DIRECTOR OF PROFESSIONAL PUBLICATIONS

Beverly Brittan Cook

MANAGING EDITOR

Orit Lowy Chicherio

ASSISTANT MANAGING EDITOR

Susan White Hale

ASSISTANT EDITORS

Jeffrey Scott Jones
Sharon L. Thomas

PUBLICATIONS ASSISTANT

Gail Croom

ADVERTISING COORDINATOR

Peggy Donovan

Mission Statements for *Diabetes Care* and *Diabetes*

Diabetes Care publishes original articles and reviews of human and clinical research intended to increase knowledge, stimulate research, and promote better management of people with diabetes mellitus. Emphasis is on human studies reporting on the pathophysiology and treatment of diabetes and its complications; genetics; epidemiology; psychosocial adaptation; education; and the development, validation, and application of accepted and new therapies. Topics covered are of interest to clinically oriented physicians, researchers, epidemiologists, psychologists, diabetes educators, and other professionals.

Diabetes publishes original research about the physiology and pathophysiology of diabetes mellitus. Submitted manuscripts can report any aspect of laboratory, animal, or human research. Emphasis is on investigative reports focusing on areas such as the pathogenesis of diabetes and its complications, normal and pathological pancreatic islet function and intermediary metabolism, pharmacological mechanisms of drug and hormone action, and biochemical and molecular aspects of normal and abnormal biological processes. Studies in the areas of diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus are not published.

All manuscripts and other editorial correspondence should be sent by first class mail to David C. Robbins, MD, Editor, *Diabetes Care*, University of Vermont, Department of Medicine, Metabolic Unit, Given C-352, Burlington, VT 05405. Manuscripts and correspondence regarding review articles should be sent to Ralph A. DeFronzo, MD, Review Editor, *Diabetes Care*, Department of Medicine, Division of Diabetes, UT-HSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78284.

Diabetes Care publishes only original material. When submitting a manuscript, authors must state in their transmittal letter that the material has not been previously published or is not currently being submitted to another journal.

Manuscripts should be prepared in accord with the requirements specified in the document "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," *Annals of Internal Medicine* 96:766-71, 1982. An "Information for Authors" page containing specifications for manuscript preparation appears in the January and June issues of each volume.

All material published in *Diabetes Care* is copyrighted by the American Diabetes Association, Inc. All manuscripts submitted to *Diabetes Care* must include a transmittal letter stating the following before they will be considered for publication. "In consideration of ADA reviewing my (our) submission, the undersigned author(s) transfers, assigns, or otherwise conveys all copyright ownership to ADA in the event the work is published." Permission to reproduce copyrighted material from *Diabetes Care* will be granted for limited, noncommercial purposes. Permission requests should be addressed to the Permissions Editor, ADA, 1660 Duke St., Alexandria, VA 22314 and should be accompanied by a letter of permission from the senior author of the article.

Diabetes Care (ISSN 0149-5992) is published 10 times per year (Jan, Feb, Mar, Apr, May, Jun, Jul/Aug, Sept, Oct, Nov/Dec) by the American Diabetes Association, Inc., 1660 Duke Street, Alexandria, VA 22314. The annual subscription rate is \$65 for individuals in the U.S. and Canada. Professional Membership dues include \$35 designated for *Diabetes Care*. The annual rate for all foreign subscriptions, excluding Canada, is \$95. The fee for individual copies is \$8 in the U.S. and Canada and \$10 in all other countries. Second class postage paid at Alexandria, Virginia 22314, and at additional mailing offices. POSTMASTER: Send change of address to *Diabetes Care*, American Diabetes Association, Inc., P.O. Box 2055, Harlan, IA 51593-0238.

Diabetes Care is listed in *Science Citation Index*, *Current Contents/Life Sciences*, *Current Contents/Clinical Medicine*, *SCISEARCH*, *ISI/BIOMED* databases, and *Automatic Subject Citation Alert*. *Diabetes Care* is available online on *BRS Colleague*. For more information call 800-468-0908. It is also available in machine-readable format from University Microfilms International. *Diabetes Care* is printed on acid-free paper starting with Vol. 11(1), 1988.

© 1990 by the American Diabetes Association, Inc.

American Diabetes Association Officers 1989-1990

CHAIRMAN OF THE BOARD

Sterling Tucker

PRESIDENT

Sherman M. Holvey, MD

CHAIRMAN OF THE BOARD-ELECT

Arnold Bereson

PRESIDENT-ELECT

Edward S. Horton, MD

SENIOR VICE-PRESIDENT

Mary Lou Maras, RD

VICE-CHAIRMAN OF THE BOARD

Todd E. Leigh

VICE-PRESIDENTS

Charlene Freeman, RN

Jay S. Skyler, MD

SECRETARY

Ross V. Hickey, Jr.


TREASURER

Douglas E. Lund

EXECUTIVE VICE-PRESIDENT

Robert S. Bolan

 **American Diabetes Association, Inc.**



RoTAG™ COMPLETES THE DIABETIC PROFILE:

Comprehensive Information

The RoTAG Fructosamine (glycated protein) Assay, in conjunction with the fasting glucose test and the glycated hemoglobin (HBA_{1c}) assay, gives you the most comprehensive information on the glycemic status of your diabetic patients.

Sensitive to Change

The RoTAG Assay is sensitive to changes in average glucose levels over the preceding 1-3 weeks, making it ideal for determining therapeutic adjustments, monitoring glycemia in pregnancy, and for the routine management of diabetic patients.

Complete Profile

When evaluating your diabetic patients, include the RoTAG Assay in your laboratory requests. If you would like more information, call 1-800-526-1247 or write:

Roche Diagnostic Systems

a subsidiary of Hoffmann-La Roche Inc.

Roche Diagnostic Systems, Inc.
One Sunset Avenue
Montclair, New Jersey 07042-5199



IN THIS ISSUE

Biguanides: Back Again?

Although phenformin was banned in this country because of its association with lactic acidosis, interest continues with biguanides, perhaps because this class of drugs appears tailor-made for overweight non-insulin-dependent diabetes mellitus (NIDDM) patients with hyperlipidemia. Wu et al. (p. 1) report results of a study indicating that another biguanide, metformin, may have beneficial effects on carbohydrate and lipid metabolism in patients with NIDDM, independent of changes in insulin secretion and sensitivity. Their observations also suggest that metformin does not have the profound effects on lactic acid concentrations as phenformin.

Many Faces of MODY


Maturity-onset diabetes of youth (MODY) was first described by Fajans and Conn 30 yr ago. Fajans (p. 49) summarizes the distinctive manifestations of this autosomal-dominant disorder, its clinical course, pathogenesis, and treatment. MODY appears to encompass ≥ 2 disorders, as evidenced by varying insulin levels among patients and their response to treatments such as oral hypoglycemic agents. On the other hand, insulin resistance or a structurally abnormal insulin molecule may lead to metabolic abnormalities. By definition, insulin-dependent diabetes expresses itself at an early age; nevertheless, people afflicted with MODY appear to be subject to the same complications. Research into the genetics and pathogenesis of MODY may be worthwhile as we attempt to understand the more common varieties of non-insulin-dependent diabetes.

Ketoacidosis and Cerebral Edema

Most patients in diabetic ketoacidosis overcome the crisis uneventfully and make a complete recovery. Why then do some patients, apparently no more critically ill and handled in a similar fashion by the same personnel, develop the catastrophic complication of cerebral edema? These issues are considered in a detailed analysis by Rosenbloom (p. 22) of nearly 100 patients who developed intracerebral complications during the course of treatment for ketoacidosis. Although it answers few questions, this article provides food for thought regarding current therapy for ketoacidosis and cerebral edema and anticipated outcome.

Pregnancy: The Eyes Have It

Does pregnancy accelerate the progression of diabetic retinopathy? If so, is it pregnancy or the rapid institution of strict glycemic control advocated in pregnancy that is responsible? Previous studies addressing these questions have yielded conflicting results. Klein et al. (p. 34) report the optical findings of 133 women evaluated during and after pregnancy and compared them with 241 nonpregnant diabetic control subjects. Pregnancy was associated with greater progression of retinopathy relative to that of the control subjects. Furthermore, the rate of progression in pregnant women correlated positively with higher glycosylated hemoglobin levels, suggesting that worsening of retinopathy did not reflect a recent imposition of tight glycemic control.




Increasing the risk of
Peripheral Arterial Disease

Diabetes stacks the odds against microcirculatory flow

In diabetes, atherosclerotic changes occur above *and* below the knee, often involving smaller vessels and multisegmental occlusions.¹ Diabetes has also been associated with decreased red cell flexibility, and increasing fibrinogen levels, platelet aggregation and platelet adherence, factors which predispose patients to peripheral arterial disease.¹

Duration of Diabetes	Incidence of PAD
10 years	15%
20 years	45%



Trental[®] improves microcirculatory flow and lifestyle for many diabetics with PAD

Trental[®] (pentoxifylline) increases red cell flexibility² while decreasing elevated plasma fibrinogen levels,³ aggregation of platelets⁴ and red cells.⁵ The resulting increase in microcirculatory flow enhances tissue perfusion and oxygenation.⁶

With Trental, patients experience significant improvement in pain-free walking distance, paresthesia, skin temperature and subjective overall response.⁷

Not a vasodilator • Not an anticoagulant • Not related to aspirin or dipyridamole

Trental[®] 400 mg Tablets
(pentoxifylline)



**The only proven-effective agent for intermittent claudication,
a symptom of peripheral arterial disease**

Please see references and brief summary of prescribing information on following page.

Trental[®] can improve function and symptoms, but is not intended to replace more definitive therapy, such as surgery.

References:

- Levin ME, Sicard GA: Evaluating and treating diabetic peripheral vascular disease, Part I. *Clinical Diabetes* May/June 1987; 2.
- Stormer B, Kleinschmidt K, Loose D, et al: Rheological changes in the blood of patients with chronic arterial occlusive disease after the administration of vasoactive drugs. *Curr Med Res Opin* 1977; 4:588-595.
- Perego MA, Sergio G, Artale F: Haemorrhological aspects of the pathophysiology and clinical features of peripheral occlusive arterial disease. *Pharmatherapeutica* 1983; 3(1):91.
- Seiffge D: *IRCS Med Sci* 1980; 8:727.
- Lowe GDO, Drummond MM, Forbes CD, et al: Blood and plasma viscosity in prediction of venous thrombosis. Abstracts: 77. International Symposium on Filterability and Red Blood Cell Deformability, Göteborg, Sweden, Sep 11-13, 1980.
- Ehrly AM: Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication. *IRCS Med Sci* 1982; 10:401.
- Schubotz R: Double-blind trial of pentoxifylline in diabetes with peripheral vascular disorders. *Pharmatherapeutica* 1976; 1(3):172-179.

Trental® (pentoxifylline) Tablets, 400 mg

A brief summary of the Prescribing Information follows.

INDICATIONS AND USAGE:

Trental® (pentoxifylline) is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Trental® (pentoxifylline) can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

CONTRAINDICATIONS:

Trental® (pentoxifylline) should not be used in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

PRECAUTIONS:

General: Patients with chronic occlusive arterial disease of the limbs frequently show other manifestations of arteriosclerotic disease. Trental® (pentoxifylline) has been used safely for treatment of peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, but there have been occasional reports of angina, hypotension, and arrhythmia. Controlled trials do not show that Trental® (pentoxifylline) causes such adverse effects more often than placebo, but, as it is a methylxanthine derivative, it is possible some individuals will experience such responses.

Drug Interactions: Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Trental® (pentoxifylline) with and without anticoagulants or platelet aggregation inhibitors. Patients on warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examinations for bleeding including hematocrit and/or hemoglobin. Trental® (pentoxifylline) has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, anti-diabetic agents, and antiarrhythmics, without observed problems. Small decreases in blood pressure have been observed in some patients treated with Trental® (pentoxifylline); periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. If indicated, dosage of the antihypertensive agents should be reduced.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term studies of the carcinogenic potential of pentoxifylline were conducted in mice and rats by dietary administration of the drug at doses up to approximately 24 times (570 mg/kg) the maximum recommended human daily dose (MRHD) of 24 mg/kg for 18 months in mice and 18 months in rats with an additional 6 months without drug exposure in the latter. No carcinogenic potential for pentoxifylline was noted in the mouse study. In the rat study, there was a statistically significant increase in benign mammary fibroadenomas in females in the high dose group (24 x MRHD). The relevance of this finding to human use is uncertain since this was only a marginal statistically significant increase for a tumor that is common in aged rats. Pentoxifylline was devoid of mutagenic activity in various strains of *Salmonella* (Ames test) when tested in the presence and absence of metabolic activation.

Pregnancy: Category C. Teratogenic studies have been performed in rats and rabbits at oral doses up to about 25 and 10 times the maximum recommended human daily dose (MRHD) of 24 mg/kg, respectively. No evidence of fetal malformation was observed. Increased resorption was seen in rats at 25 times MRHD. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Trental® (pentoxifylline) should be used during pregnancy only if clearly needed.

Nursing Mothers: Pentoxifylline and its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for pentoxifylline in rats, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in children below the age of 18 years have not been established.

ADVERSE REACTIONS:

Clinical trials were conducted using either controlled-release Trental® (pentoxifylline) tablets for up to 60 weeks or immediate-release Trental® (pentoxifylline) capsules for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid to tid and in the capsule studies, 200-400 mg tid.

The table summarizes the incidence (in percent) of adverse reactions considered

drug related, as well as the numbers of patients who received controlled-release Trental® (pentoxifylline) tablets, immediate-release Trental® (pentoxifylline) capsules, or the corresponding placebos. The incidence of adverse reactions was higher in the capsule studies (where dose related increases were seen in digestive and nervous system side effects) than in the tablet studies. Studies with the capsule include domestic experience, whereas studies with the controlled-release tablets were conducted outside the U.S. The table indicates that in the tablet studies few patients discontinued because of adverse effects.

INCIDENCE (%) OF SIDE EFFECTS

	Controlled-Release Tablets		Immediate-Release Capsules	
	Trental® (321)	Placebo (128)	Trental® (177)	Placebo (138)
(Numbers of Patients at Risk) Discontinued for Side Effect	3.1	0	9.6	7.2
CARDIOVASCULAR SYSTEM				
Angina/Chest Pain	0.3	—	1.1	2.2
Arrhythmia/Palpitation	—	—	1.7	0.7
Flushing	—	—	2.3	0.7
DIGESTIVE SYSTEM				
Abdominal Discomfort	—	—	4.0	1.4
Belching/Flatus/Bloating	0.6	—	9.0	3.6
Diarrhea	—	—	3.4	2.9
Dyspepsia	2.8	4.7	9.6	2.9
Nausea	2.2	0.8	28.8	8.7
Vomiting	1.2	—	4.5	0.7
NERVOUS SYSTEM				
Agitation/Nervousness	—	—	1.7	0.7
Dizziness	1.9	3.1	11.9	4.3
Drowsiness	—	—	1.1	5.8
Headache	1.2	1.6	6.2	5.8
Insomnia	—	—	2.3	2.2
Tremor	0.3	0.8	—	—
Blurred Vision	—	—	2.3	1.4

Trental® (pentoxifylline) has been marketed in Europe and elsewhere since 1972. In addition to the above symptoms, the following have been reported spontaneously since marketing or occurred in other clinical trials with an incidence of less than 1%; the causal relationship was uncertain:

- Cardiovascular—dyspnea, edema, hypotension.
- Digestive—anorexia, cholecystitis, constipation, dry mouth/thirst.
- Nervous—anxiety, confusion.
- Respiratory—epistaxis, flu-like symptoms, laryngitis, nasal congestion.
- Skin and Appendages—brittle fingernails, pruritus, rash, urticaria, angioedema.
- Special Senses—blurred vision, conjunctivitis, earache, scotoma.
- Miscellaneous—bad taste, excessive salivation, leukopenia, malaise, sore throat/swollen neck glands, weight change.

A few rare events have been reported spontaneously worldwide since marketing in 1972. Although they occurred under circumstances in which a causal relationship with pentoxifylline could not be established, they are listed to serve as information for physicians: Cardiovascular—angina, arrhythmia, tachycardia; Digestive—hepatitis, jaundice, increased liver enzymes; and Hemic and Lymphatic—decreased serum fibrinogen, pancytopenia, aplastic anemia, purpura, thrombocytopenia.

OVERDOSAGE:

Overdosage with Trental® (pentoxifylline) has been reported in children and adults. Symptoms appear to be dose related. A report from a poison control center on 44 patients taking overdoses of enteric-coated pentoxifylline tablets noted that symptoms usually occurred 4-5 hours after ingestion and lasted about 12 hours. The highest amount ingested was 80 mg/kg; flushing, hypotension, convulsions, somnolence, loss of consciousness, fever, and agitation occurred. All patients recovered.

In addition to symptomatic treatment and gastric lavage, special attention must be given to supporting respiration, maintaining systemic blood pressure, and controlling convulsions. Activated charcoal has been used to adsorb pentoxifylline in patients who have overdosed.

DOSAGE AND ADMINISTRATION:

The usual dosage of Trental® (pentoxifylline) in controlled-release tablet form is one tablet (400 mg) three times a day with meals. While the effect of Trental® (pentoxifylline) may be seen within 2 to 4 weeks, it is recommended that treatment be continued for at least 8 weeks. Efficacy has been demonstrated in double-blind clinical studies of 6 months duration. Digestive and central nervous system side effects are dose related. If patients develop these side effects it is recommended that the dosage be lowered to one tablet twice a day (800 mg/day). If side effects persist at this lower dosage, the administration of Trental® (pentoxifylline) should be discontinued. Edition 2/88 Trental® REG TM HOECHST AG

Hoechst-Roussel Pharmaceuticals Inc.
Somerville, New Jersey 08876



The name and logo HOECHST are registered trademarks of Hoechst AG

Help your patients take a step toward early detection and treatment of P.A.D....

Send away today or ask your Hoechst-Roussel representative for your free supply of our patient education booklet, "Step Lively".



Name _____
Address _____
City _____ State _____ Zip _____

Cut out and mail to: Step Lively, HOECHST-ROUSSEL PHARMACEUTICALS INC., P.O. Box 831, Andover, New Jersey 07821

Trental® 400 mg Tablets
(pentoxifylline)

The only proven-effective agent for intermittent claudication, a symptom of peripheral arterial disease

40


<35

What's a common denominator of most heart attack victims?

HDL < 35 mg/dL

Mixed hyperlipidemias—elevated cholesterol *and* triglycerides—are common among heart attack victims,¹ and nearly two-thirds of people who developed myocardial infarction in the PROCAM Trial had a low (< 35 mg/dL) baseline level of HDL cholesterol.²

HEART ATTACK PATIENTS
(PROCAM TRIAL)²



PARKE-DAVIS

© 1989 Warner-Lambert Company

A powerful
case for

LOPID[®] 
BID
(gemfibrozil) 600-mg
Tablets

Raised low HDL 25%

—in patients whose baseline HDL was below 35 mg/dL in the landmark Helsinki Heart Study (HHS).³

Reduced heart attack incidence* up to 62%

—in these HHS patients and 45% in HHS patients whose baseline HDL was below the median (46.4 mg/dL). Incidence of serious coronary events was similar for LOPID and placebo subgroups with baseline HDL above the median (46.4 mg/dL).³

Raised HDL levels 1½ to 3 times more effectively than lovastatin

—in a 12-week, double-blind, randomized trial among patients with moderate to severe hyperlipidemia. Lovastatin achieved greater reductions in total serum cholesterol than gemfibrozil in this study population.⁴

RAISES HDL DRAMATICALLY REDUCES HEART ATTACK

LOPID is indicated for reducing the risk of coronary heart disease (CHD) in Type IIb patients with low HDL, in addition to elevated LDL and triglycerides, and who have had an inadequate response to weight loss, diet, exercise, and other pharmacologic agents such as bile acid sequestrants and nicotinic acid.

*Defined as a combination of definite coronary death and/or definite myocardial infarction.

References: 1. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. *J Clin Invest.* 1973;52:1533-1543. 2. Assmann G, Schulte H. PROCAM-Trial: Prospective Cardiovascular Münster Trial. Zürich: Panscientia Verlag; 1986:8-9. 3. Data on file, Medical Affairs Dept, Parke-Davis 4. Tikkanen MJ, Helve E, Jäättelä A, et al. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. *Am J Cardiol.* 1988;62:35J-43J.

Please see last page of this advertisement for warnings, contraindications, and brief summary of prescribing information.

Lopid® (Gemfibrozil Capsules and Tablets)

Before prescribing, please see full prescribing information.

A Brief Summary follows.

CONTRAINDICATIONS. 1. Hepatic or severe renal dysfunction, including primary biliary cirrhosis.

2. Preexisting gallbladder disease (See WARNINGS).

3. Hypersensitivity to gemfibrozil.

WARNINGS. 1. Because of chemical, pharmacological, and clinical similarities between gemfibrozil and clofibrate, the adverse findings with clofibrate in two large clinical studies may also apply to gemfibrozil. In the first of those studies, the Coronary Drug Project, 1000 subjects with previous myocardial infarction were treated for five years with clofibrate. There was no difference in mortality between the clofibrate-treated subjects and 3000 placebo-treated subjects, but twice as many clofibrate-treated subjects developed cholelithiasis and cholecystitis requiring surgery. In the other study, conducted by the World Health Organization (WHO), 5000 subjects without known coronary heart disease were treated with clofibrate for five years and followed one year beyond. There was a statistically significant, 29%, higher total mortality in the clofibrate-treated than in a comparable placebo-treated control group. The excess mortality was due to a 33% increase in noncardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. The higher risk of clofibrate-treated subjects for gallbladder disease was confirmed.

During the Helsinki Heart Study and in the 1½ year follow-up period since the trial was completed, mortality from any cause was 59 (2.9%) in the Lopid group and 55 (2.7%) in the placebo group. Mortality from any cause during the double-blind portion of the study was 44 deaths in the Lopid group and 43 in the placebo group. Because of the more limited size of the Helsinki Heart Study, this result is not statistically significantly different from the 29% excess mortality seen in the clofibrate group in the separate WHO study. Noncoronary heart disease related mortality showed a 58% greater trend in the Lopid group (43 vs 27 patients in the placebo group, $p=0.056$).

In the Helsinki Heart Study, the incidence of total malignancies discovered during the trial and in the 1½ years since the trial was completed was 39 in the Lopid group and 29 in the placebo group (difference not statistically significant). This includes 5 basal cell carcinomas in the Lopid group and none in the placebo group ($p=0.06$; historical data predicted an expected 4.7 cases in the placebo group). GI malignancies and deaths from malignancies were not statistically different between Lopid and placebo subgroups. Follow-up of the Helsinki Heart Study participants will provide further information on cause-specific mortality and cancer morbidity.

2. A gallstone prevalence substudy of 450 Helsinki Heart Study participants showed a trend toward a greater prevalence of gallstones during the study within the Lopid treatment group (7.5% vs 4.9% for the placebo group, a 55% excess for the gemfibrozil group). A trend toward a greater incidence of gallbladder surgery was observed for the Lopid group (17 vs 11 subjects, a 54% excess). This result did not differ statistically from the increased incidence of cholecystectomy observed in the WHO study in the group treated with clofibrate. Both clofibrate and gemfibrozil may increase cholesterol excretion into the bile leading to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. Lopid therapy should be discontinued if gallstones are found.

3. Since a reduction of mortality from coronary artery disease has not been demonstrated and because liver and interstitial cell testicular tumors were increased in rats, Lopid should be administered only to those patients described in the INDICATIONS AND USAGE section. If a significant serum lipid response is not obtained, Lopid should be discontinued.

4. Concomitant Anticoagulants—Caution should be exercised when anticoagulants are given in conjunction with Lopid. The dosage of the anticoagulant should be reduced to maintain the prothrombin time at the desired level to prevent bleeding complications. Frequent prothrombin determinations are advisable until it has been definitely determined that the prothrombin level has stabilized.

5. Concomitant therapy with Lopid and Mevacor® (lovastatin) has been associated with rhabdomyolysis, markedly elevated creatine kinase (CK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure. In most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefit of combined therapy with lovastatin and gemfibrozil does not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure (See Drug Interactions). The use of fibrates alone, including Lopid, may occasionally be associated with myositis. Patients receiving Lopid and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myositis, including serum creatine kinase level determination. If myositis is suspected or diagnosed, Lopid therapy should be withdrawn.

6. Cataracts—Subcapsular bilateral cataracts occurred in 10%, and unilateral in 6.3% of male rats treated with gemfibrozil at 10 times the human dose.

PRECAUTIONS. 1. **Initial Therapy**—Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal. Before instituting Lopid therapy, every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities.

2. **Continued Therapy**—Periodic determination of serum lipids should be obtained, and the drug withdrawn if lipid response is inadequate after 3 months of therapy.

3. **Drug Interactions**—(A) **Lovastatin:** Rhabdomyolysis has occurred with combined gemfibrozil and lovastatin therapy. It may be seen as early as 3 weeks after initiation of combined therapy or after several months. In most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefit of combined therapy with lovastatin and gemfibrozil does not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure. There is no assurance that periodic monitoring of creatine kinase will prevent the occurrence of severe myopathy and kidney damage.

(B) **Anticoagulants:** CAUTION SHOULD BE EXERCISED WHEN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH LOPID. THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN LEVEL HAS STABILIZED.

4. **Carcinogenesis, Mutagenesis, Impairment of Fertility**—Long-term studies have been conducted in rats and mice at one and ten times the human dose. The incidence of benign liver nodules and liver carcinomas was significantly increased in high dose male rats. The incidence of liver carcinomas increased also in low dose males, but this increase was not statistically significant ($p=0.1$). In high dose female rats, there was a significant increase in the combined incidence of benign, and malignant liver neoplasms. In male and female mice, there were no statistically significant differences

Lopid® (Gemfibrozil Capsules and Tablets)

from controls in the incidence of liver tumors, but the doses tested were lower than those shown to be carcinogenic with other fibrates.

Male rats had a dose-related and statistically significant increase of benign Leydig cell tumors at 1 and 10 times the human dose.

Electron microscopy studies have demonstrated a florid hepatic peroxisome proliferation following Lopid administration to the male rat. An adequate study to test for peroxisome proliferation has not been done in humans but changes in peroxisome morphology have been observed. Peroxisome proliferation has been shown to occur in humans with either of two other drugs of the fibrate class when liver biopsies were compared before and after treatment in the same individual.

Administration of approximately three or ten times the human dose to male rats for 10 weeks resulted in a dose-related decrease of fertility. Subsequent studies demonstrated that this effect was reversed after a drug-free period of about eight weeks, and it was not transmitted to the offspring.

5. **Pregnancy Category B**—Reproduction studies have been performed in the rat at doses 3 and 9 times the human dose, and in the rabbit at 2 and 6.7 times the human dose. These studies have revealed no evidence of impaired fertility in females or harm to the fetus due to Lopid. Minor fetotoxicity was manifested by reduced birth rates observed at the high dose levels. No significant malformations were found among almost 400 offspring from 36 litters of rats and 100 fetuses from 22 litters of rabbits.

There are no studies in pregnant women. In view of the fact that Lopid is tumorigenic in male and female rats, the use of Lopid in pregnancy should be reserved for those patients where the benefit clearly outweighs the possible risk to the patient or fetus.

6. **Nursing Mothers**—Because of the potential for tumorigenicity shown for gemfibrozil in rats, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

7. **Hematologic Changes**—Mild hemoglobin, hematocrit and white blood cell decreases have been observed in occasional patients following initiation of Lopid therapy. However, these levels stabilize during long-term administration. Rarely, severe anemia, leukopenia, thrombocytopenia, and bone marrow hypoplasia have been reported. Therefore, periodic blood counts are recommended during the first 12 months of Lopid administration.

8. **Liver Function**—Abnormal liver function tests have been observed occasionally during Lopid administration, including elevations of AST (SGOT), ALT (SGPT), LDH, bilirubin, and alkaline phosphatase. These are usually reversible when Lopid is discontinued. Therefore periodic liver function studies are recommended and Lopid therapy should be terminated if abnormalities persist.

9. **Use in Children**—Safety and efficacy in children have not been established.

ADVERSE REACTIONS. In the double-blind controlled phase of the Helsinki Heart Study, 2046 patients received Lopid for up to 5 years. In that study, the following adverse reactions were statistically more frequent in subjects in the Lopid group (placebo incidence in parentheses): gastrointestinal reactions, 34.2%

(23.8%); dyspepsia, 19.6% (11.9%); abdominal pain, 9.8% (5.6%); acute appendicitis (histologically confirmed in most cases where data are available), 1.2% (0.6%); atrial fibrillation, 0.7% (0.1%).

Adverse events reported by more than 1% of subjects, but without a significant difference between groups (placebo incidence in parentheses) were: diarrhea, 7.2% (6.5%); fatigue, 3.8% (3.5%); nausea/vomiting, 2.5% (2.1%); eczema, 1.9% (1.2%); rash, 1.7% (1.3%); vertigo, 1.5% (1.3%); constipation, 1.4% (1.3%); headache, 1.2% (1.1%).

Gallbladder surgery was performed in 0.9% of Lopid and 0.5% of placebo subjects, a 64% excess, which is not statistically different from the excess of gallbladder surgery observed in the clofibrate compared to the placebo group of the WHO study.

Nervous system and special senses adverse reactions were more common in the Lopid group. These included hypesthesia, paresthesias, and taste perversion. Other adverse reactions that were more common among Lopid treatment group subjects but where a causal relationship was not established include cataracts, peripheral vascular disease, and intracerebral hemorrhage.

From other studies it seems probable that Lopid is causally related to the occurrence of **musculoskeletal symptoms** (See WARNINGS), and to **abnormal liver function tests** and **hematologic changes** (See PRECAUTIONS).

Reports of viral and bacterial infections (common cold, cough, urinary tract infections) were more common in gemfibrozil-treated patients in other controlled clinical trials of 805 patients.

Additional adverse reactions that have been reported for gemfibrozil are listed below by system. These are categorized according to whether a causal relationship to treatment with Lopid is probable or not established:

CAUSAL RELATIONSHIP PROBABLE: *Gastrointestinal:* cholestatic jaundice; *Central Nervous System:* dizziness, somnolence, paresthesia, peripheral neuritis, decreased libido, depression, headache; *Eye:* blurred vision; *Genitourinary:* impotence; *Musculoskeletal:* myopathy, myasthenia, myalgia, painful extremities, arthralgia, synovitis, rhabdomyolysis (see WARNINGS and Drug Interactions under PRECAUTIONS); *Clinical Laboratory:* increased creatine phosphokinase, increased bilirubin, increased liver transaminases (AST [SGOT], ALT [SGPT]), increased alkaline phosphatase; *Hematopoietic:* anemia, leukopenia, bone marrow hypoplasia, eosinophilia; *Immunologic:* angioedema, laryngeal edema, urticaria; *Integumentary:* exfoliative dermatitis, rash, dermatitis, pruritus.

CAUSAL RELATIONSHIP NOT ESTABLISHED: *General:* weight loss; *Cardiac:* extrasystoles; *Gastrointestinal:* pancreatitis, hepatoma, colitis; *Central Nervous System:* confusion, convulsions, syncope; *Eye:* retinal edema; *Genitourinary:* decreased male fertility; *Clinical Laboratory:* positive antinuclear antibody; *Hematopoietic:* thrombocytopenia; *Immunologic:* anaphylaxis, Lupus-like syndrome, vasculitis; *Integumentary:* alopecia.

DOSAGE AND ADMINISTRATION. The recommended dose for adults is 1200 mg administered in two divided doses 30 minutes before the morning and evening meal.

MANAGEMENT OF OVERDOSE. While there has been no reported case of overdose, symptomatic supportive measures should be taken should it occur.

References: 1. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. *N Engl J Med* 1987;317:1237-1245. 2. Manninen V, Elo O, Frick MH, et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. *JAMA* 1988; 260:641-651. 3. Nikkila EA: Familial lipoprotein lipase deficiency and related disorders of chylomicron metabolism. In Stanbury J. B. et al. (eds.): *The Metabolic Basis of Inherited Disease*, 5th ed., McGraw-Hill, 1983, Chap. 30, pp. 622-642.

Caution—Federal law prohibits dispensing without prescription.

PARKE-DAVIS
Div of Warner-Lambert Co
Morris Plains, NJ 07950 USA

0737G013

PD-56-JA-5860-P-1(12-89)

LOPID® (gemfibrozil) 600-mg Tablets
RAISES HDL...DRAMATICALLY
REDUCES HEART ATTACK

Joslin-style diabetes care comes to the Northeast... the Midwest...the Southeast


Joslin. A name that has meant excellence in diabetes treatment and education for more than 90 years. Now, the patented style of care that has drawn thousands each year to Joslin Diabetes Center in Boston is available at carefully selected institutions around the country.

Joslin Diabetes Clinics are open at:

- *Memorial Medical Center of Jacksonville, FL*
- *Methodist Hospital of Indiana in Indianapolis, IN*
- *Saint Barnabas Medical Center in Livingston, NJ*
- *The Western Pennsylvania Hospital in Pittsburgh, PA*

Each offers complete diabetes services including medical care by trained diabetes specialists, nutrition counseling, and one-to-one and group diabetes education. Expert care for diabetes related complications such as eye, kidney and foot problems are provided by selected specialists located at the major metropolitan hospitals with which the Joslin Clinics are associated.

For more information on Joslin affiliates call (617) 732-2666.





"I USE THE ONE TOUCH METER WITH CONFIDENCE"

—Pediatrician Peter Bove, M.D., San Bruno, California

IT
PAYS TO BE
ACCURATE
UP TO \$100⁰⁰
CASH BACK

Offer good from 1/1/90
through 5/31/90 see
Rebate Certificate
for details


"One Touch makes accurate results easy to achieve."

"I can't afford to worry about the accuracy of my blood glucose test results. That's why I use the One Touch® Blood Glucose System from LifeScan."

"In testing my own blood glucose I have found it more difficult to make a mistake with One Touch, it's so simple."

"I use One Touch with confidence in testing my own blood glucose. And I recommend One Touch with confidence for my patients."

The One Touch System dramatically simplifies blood glucose testing. Results are obtained with only three easy steps.



Insert
test strip

Press
power

Apply
sample

Accurate results are easy to achieve with testing this simple. The One Touch System reduces the chance of user error because it eliminates three major demands on the user: Starting the Test, Timing the Test, and Removing the Blood. And that means greater accuracy where it matters most: in the hands of the people who use it¹.

To find out more about the One Touch Blood Glucose Monitoring System call:

Toll Free

United States

1 800 227-8862

Canada

1 800 663-5521

1. Jovanovic-Peterson L., Peterson C., Dudley J., Kilo C., Ellis B.: Identifying sources of error in self-monitoring of blood glucose. *Diabetes Care* 1988; 11 (10) 791-794.

LIFESCAN INC.

a Johnson & Johnson company
Milpitas, California 95035

ENDOCRINOLOGIST/DIABETOLOGIST: A unique opportunity to join the four member Endocrinology, Diabetes and Metabolic Diseases Section of the Department of Internal Medicine of a 290 physician multispecialty medical clinic in desirable Minneapolis-St. Paul area. Section members also work with the International Diabetes Center as relates to diabetes management.

We have two new positions to offer and candidates should be Endocrine board eligible or board certified and enjoy a wide diversity of patient care. Opportunities exist for teaching and research.

Salary and benefits are highly competitive. Send CV and letters of inquiry to Patrick Moylan, Park Nicollet Medical Center, 5000 West 39th Street, Minneapolis, Minnesota 55416



Park Nicollet
Medical Center

DIRECTOR OF DIABETES PROGRAM, Winthrop-University Hospital. An academic endocrinologist is sought to join the Division of Endocrinology and Metabolism. The Division established the first program in New York State to be recognized by the ADA as meeting the National Standards on Diabetes Patient Education Programs. This position will provide leadership in further development of our clinical and teaching programs and will initiate new research activities. Candidate should be an outstanding clinician and teacher with demonstrated productivity in clinical research. Board certification in endocrinology is desired and participation in teaching and ongoing research in endocrinology in the Division is required. Candidates must have demonstrated qualities to be effective members of a team. Qualifications for academic appointment at the assistant professor level is appropriate. Winthrop-University Hospital is a 533-bed teaching center of the Health Sciences Center, SUNY at Stony Brook. Send CV to John F. Aloia, M.D., Chairman, Department of Medicine, Winthrop-University Hospital, 259 First Street, Mineola, NY 11501.

THE AMERICAN DIABETES ASSOCIATION
THIRD ANNUAL GOVERNMENT RELATIONS SEMINAR
AND
CONGRESSIONAL RECEPTION
March 18-20, 1990

CELEBRATING THE AMERICAN DIABETES ALERT
AND ADA'S 50TH ANNIVERSARY

Washington Marriott
1221 22nd Street, N.W.
Washington, D.C.

Take part in the legislative process and in-depth discussions of the key legislative and regulatory issues affecting people with diabetes. Workshop topics:

- fetal tissue transplantation research* ● *the use of animals in research*
- health insurance* ● *employment discrimination* ● *food labeling*

WHO SHOULD ATTEND:

ADA Affiliate and Chapter Volunteers Representatives from Sister Organizations
ADA Staff State Legislators and Staff

YOU!

Don't miss this opportunity to meet Members of Congress, key Congressional staff, and Washington lobbyists as they offer their views on some of the hottest topics of debate in Congress today!

REGISTER NOW!

For more information and to register, call or write: Jean Whalen, The American Diabetes Association, 1660 Duke St., Alexandria, VA 22314 (703) 549-1500 (ext. 284).

Classified Advertising

Diabetes Care Classified Ad rates are:

- 1/4 Page \$475 (for members of ADA, \$350)
- 1/8 Page \$235 (for members of ADA, \$175)

For information on closing dates; Copy and Contract Policies; and Classified Advertising rates in *Diabetes*, contact:


Peggy B. Donovan
American Diabetes Association
1660 Duke Street
Alexandria, VA 22314
(800) ADA-DISC or in Virginia and
Washington DC Area dial (703) 549-1500.

*The reasons to
prescribe
Glucotrol can
pile up fast*

In Type II diabetes...

- *Glucotrol starts
controlling blood
sugar in minutes^{1,2}*
- *Once-daily dosing*



Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets 

When diet alone fails in non-insulin-dependent diabetes mellitus

*Please see brief summary
of GLUCOTROL[®] (glipizide)
prescribing information
on next page.*

As fast as
blood sugar spills,
Glucotrol
spells...

Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets

References: 1. Goebel R, Leb G: Effects of glyburide and glipizide on levels of immunoreactive insulin and blood sugar. In *Glipizide: A Worldwide Review*. Princeton, NJ, Excerpta Medica, 1984, pp 9-15. 2. Melander A, Wåhlin-Boll E: Clinical pharmacology of glipizide. *Am J Med* 1983;75:8-14.

GLUCOTROL[®] (glipizide) Tablets

Brief Summary of Prescribing Information

INDICATIONS AND USAGE: GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

CONTRAINDICATIONS: GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19, supp. 2:747-830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: Renal and Hepatic Disease: The metabolism and excretion of GLUCOTROL may be slowed in patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

Laboratory Tests: Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

Information for Patients: Patients should be informed of the potential risks and advantages of GLUCOTROL, of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to a clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control, including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

Carcinogenesis, Mutagenesis, Impairment of Fertility: A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Pregnancy: Pregnancy Category C: GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well-controlled studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

Nursing Mothers: Since some sulfonylurea drugs are known to be excreted in human milk, insulin therapy should be considered if nursing is to be continued.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas: GLUCOTROL should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL, if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

OVERDOSAGE: Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL, dialysis is unlikely to be of benefit.

DOSE AND ADMINISTRATION: There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL; in general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

Initial Dose: The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5-5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

Maximum Dose: The maximum recommended total daily dose is 40 mg.

Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.

HOW SUPPLIED: GLUCOTROL is available as white, dye-free, scored, diamond-shaped tablets imprinted as follows: 5 mg tablet—Pfizer 411 (NDC 5 mg 0049-4110-66) Bottles of 100; 10 mg tablet—Pfizer 412 (NDC 10 mg 0049-4120-66) Bottles of 100.


CAUTION: Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

ROERIG **Pfizer** A division of Pfizer Pharmaceuticals
New York, New York 10017

If you've been waiting for the last word
in non-wipe blood glucose monitoring systems...

wait no more.



Presenting

Ultra

THE ULTIMATE IN ACCURACY, SIMPLICITY AND EASE OF USE


Finally, an advanced concept in blood glucose monitoring that any diabetes patient will feel comfortable with — the first time they hold ULTRA in the palm of their hand.

The revolutionary ULTRA System is simple to operate. Highly accurate. Shirt-pocket portable. And completely non-wipe.

Just insert the test strip, turn on the power, apply the blood. The ULTRA Meter starts the test automatically. The results are crystal clear — in only 45 seconds. Plus, test data will be stored automatically in the meter's memory for future reference. Simple, easy-to-see messages guide the tester through the procedure, making user error a thing of the past.

And, unlike any other non-wipe system, ULTRA is equipped with a reliable visual-read capability that can be used in conjunction with the meter, or by itself — offering an added measure of confidence and flexibility.

Accuracy, simplicity, and ease of use — when it comes to non-wipe blood glucose monitoring, you'll agree ULTRA is the last word.




TRULY COMPACT

Only ULTRA offers so many vital features in such a small and practical package.



SIMPLICITY ITSELF

Insert test strip. Turn on power. Apply blood sample. No timing. No wiping. No blotting. Accurate single-touch test results in 45 seconds.



VISUAL-READ CAPABILITY

Revolutionary, patented test strip and color chart provide an extra measure of confidence and flexibility.



HDI • Home Diagnostics, Inc.

The Innovative Name in Diabetes Management

6 Industrial Way West, Eatontown, NJ 07724 • 1-800-342-7226 (in New Jersey and outside the USA, call (201) 542-7788)

The worldwide leader in diabetes care.



Squibb-Novio and Nordisk unite to create: Novo Nordisk Pharmaceuticals Inc.

- Leader in insulin technology: World's first NPH insulin, Lente® insulin, commercially available human and human premixed insulins (Novolin® [semi-synthetic]), and innovative delivery systems, such as NovoPen® and NovolinPen®
- Dedicated to helping healthcare professionals provide the best diabetes care possible

For additional information call 1-800-727-6500.

Novo Nordisk Pharmaceuticals Inc.

The worldwide leader in diabetes care

©Novo Nordisk Pharmaceuticals Inc. 1990